Key statistics
As of last trade Oric Pharmaceuticals Inc (ORIC:NSQ) traded at 10.94, -25.46% below its 52-week high of 14.67, set on Feb 10, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.88 |
---|---|
High | 10.99 |
Low | 10.60 |
Bid | 10.92 |
Offer | 10.93 |
Previous close | 10.85 |
Average volume | 655.70k |
---|---|
Shares outstanding | 85.22m |
Free float | 63.94m |
P/E (TTM) | -- |
Market cap | 924.68m USD |
EPS (TTM) | -1.88 USD |
Data delayed at least 15 minutes, as of Jul 15 2025 20:36 BST.
More ▼
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC
- ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing
- ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
- ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC
- ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
More ▼